AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

09 Feb
AHFS Drug Information logo
AHFS February 2021 Update

This update contains 3 new monographs and 7 revised monographs.

New monographs: Lumasiran Sodium; Berotralstat; Oliceridine Fumarate

Revised monographs: Montelukast; Brinzolamide; Brimonidine; Phentermine and Topiramate; Timolol; Betaxolol; Dorzolamide

12 Jan
AHFS Drug Information logo
AHFS January 2021 Update

This update contains 3 new monographs, 53 revised monographs and 33 new MedWatch alerts.

New monographs: Atoltivimab, Maftivimab, and Odesivimab-ebgn; Bamlanivimab; Casirivimab and Imdevimab

Revised monographs: Rivastigmine; Meloxicam; Galantamine; Travoprost; Flurbiprofen; Pregabalin; CloBAZam; Ibrutinib; Netarsudil Mesylate; Ivosidenib; Stiripentol; Solriamfetol; Pitolisant; Enfortumab Vedotin-ejfv; Fam-Trastuzumab Deruxtecan-nxki; Fenoprofen; Indomethacin; Mefenamic Acid; Naproxen; Tolmetin; Sulindac; DiazePAM; Oxazepam; Flurazepam; Clorazepate; LORazepam; ChlordiazePOXIDE; Ibuprofen; ClonazePAM; Meclofenamate; Valproate/Divalproex; Aspirin; Anticonvulsants General Statement; Carbonic Anhydrase Inhibitors General Statement; ALPRAZolam; Temazepam; Triazolam; Diflunisal; Piroxicam; Levobunolol; Ketoprofen; Diclofenac; Ketorolac; Quazepam; CloZAPine; Estazolam; Etodolac; Nabumetone; Oxaprozin; Gabapentin; Topiramate; Donepezil; Celecoxib

New MedWatch alerts on the following monographs: Meloxicam; Flurbiprofen; Fenoprofen; Indomethacin; Mefenamic Acid; Naproxen; Tolmetin; Sulindac; Ibuprofen; Meclofenamate; Aspirin; Diflunisal; Piroxicam; Ketoprofen; Diclofenac; Ketorolac; Etodolac; Nabumetone; Oxaprozin; Celecoxib; Clobazam; Diazepam; Oxazepam; Flurazepam; Clorazepate; Lorazepam; Chlordiazepoxide; Clonazepam; Alprazolam; Temazepam; Triazolam; Quazepam; Estazolam

08 Dec
AHFS Drug Information logo
AHFS December 2020 Update

This update contains 1 new monograph, 43 revised monographs and 1 discontinued monograph.

New monograph: Nifurtimox

Revised monographs: Mifepristone; Bimatoprost; Alemtuzumab (Antineoplastic); Memantine; Tolvaptan; Tafluprost; Dolutegravir; Idelalisib; Panobinostat; Parathyroid Hormone; Alemtuzumab (MS); Blinatumomab; Flibanserin; Latanoprostene bunod; Semaglutide; Pegvaliase-pqpz; Duvelisib; Inotersen; Revefenacin; Ravulizumab-cwvz; Ketamine; Esketamine; Brexanolone; Pexidartinib; Enfortumab Vedotin-ejfv; Tazemetostat; Remdesivir; Satralizumab-mwge; Levorphanol; Codeine; Meperidine; Oxymorphone; Morphine; Loxapine; Pentazocine; Hydrocodone; Butorphanol; Cathartics and Laxatives General Statement; Insulin Human; Tramadol; Latanoprost; Olanzapine; Thalidomide

Discontinued monograph: Delavirdine

10 Nov
AHFS Drug Information logo
AHFS November 2020 Update

This update contains 1 new monograph and 10 revised monographs.

New monograph: Pralsetinib

Revised monographs: Raltegravir Potassium; Ofatumumab (Antineoplastic); Tagraxofusp-erzs; Polatuzumab Vedotin-piiq; Zanubrutinib; Avapritinib; Remdesivir; Ofatumumab (Multiple Sclerosis); Opiate Agonists General Statement; Antiretroviral Agents General Statement

13 Oct
AHFS Drug Information logo
AHFS October 2020 Update

This update contains 9 new monographs, 25 revised monographs and 1 new MedWatch alert.

New monographs: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Fostemsavir; Amisulpride; Tafasitamab-cxix; Belantamab Mafodotin-blmf; Viltolarsen; Risdiplam; Ofatumumab; Satralizumab-mwge

Revised monographs: Nitric Oxide; Propofol; Influenza Vaccine Live Intranasal; Remifentanil; Golimumab; Ustekinumab; Brentuximab; Influenza Vaccine Recombinant; Elbasvir and Grazoprevir; Bictegravir, Emtricitabine, and Tenofovir Alafenamide; Glasdegib; Alpelisib; Upadacitinib; Fedratinib; Entrectinib; Remdesivir; HYDROmorphone; Neostigmine; Warfarin; Probenecid; SUFentanil; Influenza Virus Vaccine Inactivated; Immunization Schedules; Anti-infectives Available from CDC; Immunobiologic Agents Available from CDC

New MedWatch alert on the following monograph: HYDROmorphone

08 Sep
AHFS Drug Information logo
AHFS September 2020 Update

This update contains 4 new monographs, 24 revised monographs and 18 new MedWatch alerts.

New monographs: Selpercatinib; Inebilizumab-Cdon; Lurbinectedin; Decitabine And Cedazuridine

Revised monographs: Remifentanil; Tapentadol; Dolutegravir and Rilpivirine; Dolutegravir and Lamivudine; Brolucizumab; HYDROcodone; Levorphanol; Codeine; Meperidine; OxyMORphone; OxyCODONE; Morphine; Methadone; Bacitracin; Opium; Pentazocine; FentaNYL; Butorphanol; Nalbuphine; Neomycin; Opiate Agonists General Statement; SUFentanil; Buprenorphine; TraMADol

New MedWatch alerts on the following monographs: Remifentanil; Tapentadol; HYDROcodone; Levorphanol; Codeine; Meperidine; oxyMORphone; OxyCODONE; Morphine; Methadone; Opium; Pentazocine; FentaNYL; Butorphanol; Nalbuphine; SUFentanil; Buprenorphine; TraMADol

 
View more View all content updates